Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Signs CRADA With US Army to Develop RNAi-Based Antivirals

NEW YORK, April 13 (GenomeWeb News) - Alnylam Pharmaceuticals and the United States Army Medical Research Institute of Infectious Diseases plan to co-develop RNAi therapeutics targeting viruses, Alnylam said yesterday.

 

Under the Cooperative Research and Development Agreement, Alnylam will use its RNAi therapeutic platform to discover and develop agents against viruses posing "a serious biological threat to the military and public health," including hemorrhagic fever viruses, according to a company statement.

 

According to Alnylam, USAMRIID is "an organization which is uniquely positioned to collaborate in translational research for Biosafety Level 4 threats."

 

Last year, Alnylam signed a CRADA with the Department of Defense's DARPA unit to develop RNAi-based influenza therapeutics.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.